Avitaminosis (Hypovitaminosis) ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Avitaminosis (Hypovitaminosis) ' Pipeline Review, H2 2012
Published on October 2012

Report Summary


Summary

Global Markets Direct's, 'Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012', provides an overview of the indication's
therapeutic pipeline. This report provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete
with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the
therapeutic development for Avitaminosis (Hypovitaminosis). Avitaminosis (Hypovitaminosis) - Pipeline Review, Half Year is built
using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis).
- A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Avitaminosis (Hypovitaminosis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Avitaminosis (Hypovitaminosis) pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Avitaminosis (Hypovitaminosis) ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Avitaminosis (Hypovitaminosis) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) 7
Avitaminosis (Hypovitaminosis) Therapeutics under Development by Companies 9
Avitaminosis (Hypovitaminosis) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Early Clinical Stage Products 13
Avitaminosis (Hypovitaminosis) Therapeutics ' Products under Development by Companies 14
Avitaminosis (Hypovitaminosis) Therapeutics ' Products under Investigation by Universities/Institutes 15
Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development 16
Kyowa Hakko Kirin Co., Ltd. 16
Zeria Pharmaceutical Co Ltd 17
Emisphere Technologies, Inc. 18
Cytochroma Inc. 19
Avitaminosis (Hypovitaminosis) ' Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
sodium phosphate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CTAP-101 - Drug Profile 26
R&D Progress 26
KRN-23 - Drug Profile 27
R&D Progress 27
cholecalciferol - Drug Profile 28



R&D Progress 28
Avitaminosis (Hypovitaminosis) Therapeutics ' Drug Profile Updates 29
Avitaminosis (Hypovitaminosis) Therapeutics - Dormant Products 32
Avitaminosis (Hypovitaminosis) ' Product Development Milestones 33
Featured News & Press Releases 33
Sep 20, 2012: Cytochroma Initiates Phase III Study Of CTAP101 Capsules In Chronic Kidney Disease Patients 33
Nov 02, 2009: Interim Study Data Demonstrate Eligen B12 Oral Formulation Achieves Comparable Results to B12 Injection 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables

Number of Products Under Development for Avitaminosis (Hypovitaminosis), H2 2012 7
Products under Development for Avitaminosis (Hypovitaminosis) ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Kyowa Hakko Kirin Co., Ltd., H2 2012 16
Zeria Pharmaceutical Co Ltd, H2 2012 17
Emisphere Technologies, Inc., H2 2012 18
Cytochroma Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Avitaminosis (Hypovitaminosis) Therapeutics ' Drug Profile Updates 29
Avitaminosis (Hypovitaminosis) Therapeutics ' Dormant Products 32

List of Figures

Number of Products under Development for Avitaminosis (Hypovitaminosis), H2 2012 7
Products under Development for Avitaminosis (Hypovitaminosis) ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21



Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Avitaminosis (Hypovitaminosis) ' Pipeline Review, H2 2012

Recomendados

Recomendados

Más contenido relacionado

Más de ReportLinker.com

Más de ReportLinker.com (20)

Avitaminosis (Hypovitaminosis) ' Pipeline Review, H2 2012